Fiche société
The Second Affiliated Hospital of Fujian Medical University
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| QH103 Cell InjectionThis study is an open-label, single-arm clinical trial designed to evaluate the safety and tolerability of QH103 cell injection solution in adult subjects with relapsed/refractory CD19-positive B-cell lymphoma. | SEP | Phase 1 | À vérifier | China | À vérifier |
| QH103 Cell InjectionThis study is an open-label, single-arm clinical trial designed to evaluate the safety and tolerability of QH103 cell injection solution in adult subjects with relapsed/refractory CD19-positive B-cell lymphoma. | SEP | Phase 1 | Immunomodulation | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| QH103 Cell Injection | SEP | Phase 1 | NCT07367685 | Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma | NOT_YET_RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||